Try our Advanced Search for more refined results

At PTAB, Mylan Blasts AstraZeneca Over $3.5B Diabetes Meds

By Jimmy Hoover (January 25, 2017, 5:08 PM EST) -- Mylan Pharmaceuticals Inc. waged an assault Wednesday on the patent behind AstraZeneca AB's $3.5 billion diabetes drugs Onglyza and Kombiglyze, arguing in front of a Patent Trial and Appeals Board panel that the specific chemical compound claimed in the inventions would have been obvious to skilled artisans at the time....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

PTAB Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Companies

Government Agencies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!